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A B S T R A C T
Proarrhythmia usually refers to the worsening of an arrhythmia from an antiarrhyth-
mic medication. However, implantable cardioverter defibrillator (ICD) devices can 
also be proarrhythmic as is shown in the case herein presented.
I N T R O D U C T I O N
The implantable cardioverter – defibrillator (ICD) is a device that treats ventricu-
lar tachyarrhythmias (VT) when they appear in a sustained form. The device can be 
programmed to deliver the following therapies: 1) antitachycardia pacing (ATP), 2) 
cardioversion and 3) defibrillation. Contemporary devices also have the capability of 
every mode of cardiac pacing, i.e. atrial, ventricular, atrio-ventricular and biventricular 
pacing.
It is well known that antiarrhythmic drug therapy can exhibit proarrhythmic 
effects. Likewise, the antiarrhythmic apparatus can possibly aggravate an existing 
VT or cause the appearance of a new arrhythmia, attempting to convert the clinical 
tachyarrhythmia.
C A S e  R e p O R T
A case of proarrhythmic effect related to the therapeutic sequences delivered by 
an ICD is delineated in the following continuous recording of an arrhythmic event, as 
it was stored in the Holter function of the device (Fig. 1). The case in hand concerns 
a patient with ischemic cardiomyopathy, low left ventricular ejection fraction (~30%), 
sustained VT recorded on ambulatory monitoring, in whom a single chamber ICD 
had been implanted.
On the upper left quadrant there is the arrhythmia episode report, including the 
treatment details of the VT detected by the device. The rest of the slide (panels A to 
F) represents the continuous tracing of the arrhythmic event, recalled from the device’s 
memory. Each panel consists of the endocardiac ventricular electrogram (EGM) and 
the detected cardiac rhythm cycle length (in ms).
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AbbreviAtions
ATP= antitachycardia pacing
EGM= electrogram
ICD= implantable cardioverter 
defibrillator
PVC= premature ventricular contraction
VT= ventricular tachycardia
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patients with implanted defibrillating systems have been 
recorded at a rate of 5%. Directly related to the appearance 
of proarrhythmic effect are in general the following factors: 
1) high frequency of clinical VT, 2) rate of aggressiveness of 
the preprogrammed ATP protocol, 3) degree of myocardial 
dysfunction, 4) existence of myocardial ischemia, 5) coexist-
ence of electrolyte disorders.1-3
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On panel A, the basic paced rhythm (60 bpm) and a pre-
mature ventricular contraction (PVC) is recorded. On panel 
B, it is a PVC that induces a sustained VT at a rate of 185 bpm. 
The first ATP scheme is released (arrow 1) with no effect. On 
panel C, the ICD attempts to terminate the VT by a second 
ATP sequence (arrow 2), resulting in a slight acceleration of 
the ventricular rate (191 bpm). The third ATP scheme (panel 
D, arrow 3) is followed by a significant acceleration of the 
tachycardia rate (240 – 250 bpm), which caused the device 
to deliver a shock (panel E, arrow 4). Subsequently, the VT 
degenerated into ventricular fibrillation (panel F) and finally, 
a second shock of 30J (arrow 5) restored the regular rhythm.
D I S C U S S I O N
In the present example, the ICD caused worsening of the 
existing VT, before it succeeded in terminating it in the end. 
This demonstrates a proarrhythmic effect of the antiarrhyth-
mic device.
Arrhythmogenic effects of the delivered therapies in 
FIgURe 1.
